Skip to main content
. Author manuscript; available in PMC: 2016 Mar 16.
Published in final edited form as: Nat Rev Clin Oncol. 2009 Apr;6(4):229–236. doi: 10.1038/nrclinonc.2009.14

Figure 4.

Figure 4

serial MRI images from the same patient (as shown in Figure 3) with a left frontal glioblastoma treated with cediranib. Days –5 and –1 are baseline studies before initiation of treatment, followed by images on day +1, +27, +55, +111 after cediranib therapy. Top row: FLAIR images demonstrating resolution of edema with treatment. Second row: Apparent diffusion coefficient maps (measurement of water mobility) demonstrating improved water mobility (that is, less edema causing restricted diffusion) with treatment. Bottom row: White matter tractography demonstrating improvement in the architecture of white matter fiber tracts as edema resolves and mass effect and tissue displacement diminish. Abbreviations: ADC, apparent diffusion coefficient; FLAIR, fluid attenuation inversion recovery. Permission obtained from Elsevier © Batchelor, T. T., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).